Management of Kawasaki Disease in Pediatric Patients

Initial Treatment Protocol

• The American Heart Association recommends IVIG 2 g/kg as a single infusion over 10-12 hours combined with high-dose aspirin 80-100 mg/kg/day divided into four doses, initiated as early as possible within the first 10 days of fever onset 1, 2, 3, 4
• IVIG 2 g/kg as a single infusion is the cornerstone of treatment, with the highest level of evidence (Grade 1A) supporting its use within 10 days of symptom onset 1, 2, 3
• High-dose aspirin 80-100 mg/kg/day should be given in four divided doses during the acute phase 1, 2, 3, 4
• This regimen reduces coronary artery abnormality risk from 15-25% down to approximately 5% for any abnormality and 1% for giant aneurysms 4

Aspirin Dosing Algorithm

• Continue high-dose aspirin until the patient has been afebrile for 48-72 hours 4
• Then transition to low-dose aspirin 3-5 mg/kg/day as a single daily dose 1, 2, 3, 4
• Continue low-dose aspirin until 6-8 weeks after disease onset if no coronary abnormalities are present 1, 2, 3
• For children who develop coronary abnormalities, aspirin may be continued indefinitely 4

Management of IVIG-Resistant Disease

• IVIG resistance occurs in 10-20% of patients, defined as persistent or recrudescent fever ≥36 hours after completing initial IVIG infusion 4
• Administer a second dose of IVIG 2 g/kg as a single infusion for IVIG-resistant patients 1, 2, 3, 4
• Methylprednisolone 20-30 mg/kg IV for 3 days, or Infliximab 5 mg/kg IV over 2 hours as a single infusion, can be used as second-line options for IVIG-resistant cases 4

Long-Term Antiplatelet and Anticoagulation Management

• For patients with no coronary abnormalities, low-dose aspirin 3-5 mg/kg/day can be discontinued 6-8 weeks after disease onset 1, 2, 3, 4
• For patients with small coronary aneurysms, low-dose aspirin 3-5 mg/kg/day should be continued indefinitely 4
• For patients with moderate aneurysms, low-dose aspirin 3-5 mg/kg/day plus clopidogrel 1 mg/kg/day (max 75 mg/day) is recommended 4
• For patients with giant aneurysms, low-dose aspirin 3-5 mg/kg/day plus warfarin with target INR 2.0-3.0 is recommended 1, 2, 3, 4

Monitoring and Follow-Up

• Perform echocardiography at diagnosis, 2 weeks, and 6-8 weeks after treatment initiation 4
• Frequent echocardiography and ECG during the first 3 months after diagnosis, especially for giant aneurysms 4
• CRP is more accurate than ESR for monitoring inflammation after IVIG therapy, as IVIG elevates ESR 4

Critical Caveats and Common Pitfalls

• Infants <1 year are at highest risk for incomplete presentations and paradoxically have the highest rates of coronary aneurysms if untreated 4
• Incomplete KD should still be treated if there is evidence of coronary artery abnormalities or elevated inflammatory markers 4
• Never use ibuprofen in children taking aspirin for antiplatelet effects, as it antagonizes the irreversible platelet inhibition induced by aspirin 4
• Defer measles, mumps, rubella, and varicella immunizations for 11 months after high-dose IVIG administration due to interference with vaccine efficacy 4
• Annual influenza vaccination is mandatory for children on long-term aspirin therapy due to Reye syndrome risk during influenza infection 4

Post‑IVIG Management in Kawasaki Disease

Immediate Aspirin Therapy After IVIG

Treatment of IVIG‑Resistant Disease

Laboratory Monitoring Post‑IVIG

Long‑Term Antiplatelet Strategy Based on Coronary Findings

Immunization Timing After High‑Dose IVIG

Additional Safety Recommendations for Children on Aspirin

Management of New Rash After IVIG in Kawasaki Disease

Definition of IVIG Resistance

• In children with Kawasaki disease, IVIG‑resistant disease is defined as persistent or recrudescent fever lasting ≥ 36 hours after completion of the initial 2 g/kg IVIG infusion, regardless of the presence of a new rash. This definition is part of the American Heart Association (AHA) guideline for Kawasaki disease. 8

• The appearance of a new rash without accompanying fever does not satisfy criteria for IVIG resistance. The rash alone should not trigger classification as treatment failure. 9

Assessment of Post‑IVIG Rash

• If the patient is afebrile for more than 36 hours after IVIG, a new rash is most likely a benign hypersensitivity reaction to the IVIG product rather than an indication of disease progression. (AHA guideline) 8

• If fever persists or recurs ≥ 36 hours after IVIG, the rash may reflect ongoing Kawasaki disease activity and should be considered in the context of IVIG resistance. (AHA guideline) 9

Treatment Escalation Criteria

• Do not administer additional IVIG or intensify therapy based solely on the presence of a rash; escalation is reserved for fever criteria. (Class I, Level B recommendation) 8

• When persistent or recrudescent fever ≥ 36 hours after the first IVIG dose is documented, a second dose of IVIG (2 g/kg) is recommended. (AHA guideline) 9

• If fever remains after two standard IVIG doses, the guideline advises consideration of adjunctive therapy such as methylprednisolone (20–30 mg/kg IV daily for 3 days) or infliximab (5 mg/kg IV). (Class IIa, Level B) 8

Common Pitfalls to Avoid

• Confusing a post‑IVIG rash with IVIG resistance—resistance requires fever ≥ 36 hours, not rash alone. (AHA guideline) 8

• Mistaking the rash for an aspirin‑related drug reaction; aspirin should be continued at high dose (80–100 mg/kg/day) until the patient is afebrile for 48–72 hours. (AHA guideline) 8

• Assuming the rash indicates incomplete Kawasaki disease that necessitates additional diagnostic criteria; once Kawasaki disease is confirmed and initial therapy given, the rash does not alter the diagnosis. (American Heart Association, 2004 guideline) 10

Rash Resolution and Management After IVIG in Kawasaki Disease

Expected Timeline for Rash Resolution

• The American Heart Association notes that the characteristic rash of Kawasaki disease usually appears within the first 5 days of illness and is predominantly truncal with accentuation in the groin area. 11
• Following successful IVIG therapy (2 g/kg), the rash generally fades within a few days as systemic inflammation subsides; the guidelines do not prescribe a precise time frame for rash disappearance. 11

Aspirin Therapy Post‑IVIG

• The American Heart Association recommends continuing high‑dose aspirin (80–100 mg/kg/day divided into four doses) until the patient has been afebrile for 48–72 hours, regardless of whether a rash persists. 12

Monitoring Inflammation After IVIG

• The American Heart Association advises using C‑reactive protein (CRP) rather than erythrocyte sedimentation rate (ESR) to assess ongoing inflammation after IVIG, because IVIG can artificially elevate ESR values. 12

Post‑IVIG Management in Kawasaki Disease

Aspirin Therapy

• Continue high‑dose aspirin at 80–100 mg/kg/day divided into four doses until the child has been afebrile for 48–72 hours, then switch to low‑dose aspirin 3–5 mg/kg/day once daily. American Heart Association recommendation. 13
• Maintain low‑dose aspirin for 6–8 weeks after disease onset when serial echocardiograms show no coronary abnormalities. American Heart Association recommendation. 13

Definition and Monitoring of IVIG Resistance

• IVIG resistance is defined as persistent or recrudescent fever ≥36 hours after completion of the initial 2 g/kg IVIG infusion. American Heart Association definition. 14
• Temperature should be monitored closely during the 36–48‑hour window after IVIG completion to detect resistance. American Heart Association guidance. 14

Rescue Therapy for IVIG‑Resistant Disease

• If fever persists or recurs ≥36 hours after the first IVIG dose, administer a second IVIG dose of 2 g/kg as a single infusion. This is the first‑line rescue therapy (Class IIa, Level B evidence). American Heart Association recommendation. 14

Second‑Line Immunomodulatory Options (after two IVIG doses)

• Methylprednisolone 20–30 mg/kg IV daily for 3 days, with or without an oral prednisone taper, may be used. American Heart Association recommendation. 14
• Infliximab 5 mg/kg IV as a single infusion over 2 hours is an alternative second‑line option. American Heart Association recommendation. 14

Third‑Line Therapies (highly refractory disease)

• Cyclosporine may be considered (Class IIb, Level C evidence). American Heart Association recommendation. 14
• Plasma exchange is reserved for exceptional cases when all reasonable medical therapies have failed. American Heart Association recommendation (supported by additional evidence from 2004). [14][15]

Echocardiographic Surveillance

• Color‑flow Doppler with a low Nyquist limit should be used to demonstrate flow in the proximal coronary arteries. American Heart Association imaging guideline. 13

Antiplatelet Strategies Based on Coronary Findings

• Moderate coronary aneurysms (4–6 mm): low‑dose aspirin 3–5 mg/kg/day plus clopidogrel 1 mg/kg/day (maximum 75 mg/day). American Heart Association recommendation. 14
• Giant coronary aneurysms (≥8 mm): low‑dose aspirin 3–5 mg/kg/day plus warfarin (target INR 2.0–3.0) or therapeutic low‑molecular‑weight heparin. American Heart Association recommendation. 14

Late‑Presentation IVIG Indication

• Children who present after day 10 of illness should still receive IVIG if they have ongoing systemic inflammation (CRP > 3.0 mg/dL) together with either persistent fever or coronary artery aneurysms. American Heart Association guidance. 13

Aspirin Management in Kawasaki Disease – Evidence‑Based Recommendations

Acute Phase – High‑Dose Aspirin

• Initiate high‑dose aspirin 80–100 mg/kg/day divided into four doses at diagnosis, administered concurrently with a single‑infusion IVIG dose of 2 g/kg. This regimen provides anti‑inflammatory effects when combined with IVIG. 16
• Continue high‑dose aspirin until the patient has been afebrile for 48–72 hours; some centers extend therapy to day 14 of illness plus the afebrile period. 16

Transition to Low‑Dose Aspirin (Antiplatelet Phase)

• After fever resolution for 48–72 hours, switch to low‑dose aspirin 3–5 mg/kg/day given once daily for antiplatelet effect. 16
• Maintain low‑dose aspirin for 6–8 weeks after disease onset if serial echocardiograms demonstrate no coronary artery abnormalities. 16
• If any coronary artery abnormality is identified, continue low‑dose aspirin indefinitely. 16

Safety Considerations

• Avoid co‑administration of ibuprofen with aspirin in children on antiplatelet therapy, because ibuprofen antagonizes aspirin’s irreversible platelet inhibition. 16
• Provide annual influenza vaccination to all children receiving long‑term aspirin to lower the risk of Reye syndrome during influenza infection. 16
• Discontinue aspirin immediately if the child develops influenza or varicella infection; substitute an alternative antiplatelet agent (e.g., clopidogrel) during the illness to maintain antithrombotic protection while preventing Reye syndrome. 16

Guideline Recommendation

• The American Heart Association guideline (Circulation 2004) recommends high‑dose aspirin 80–100 mg/kg/day in the acute phase, citing decades of clinical experience and an established safety profile when used together with IVIG. 16